Hiroshi Sasano

Dr. Hiroshi Sasano

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
HSHiroshi Sasano
Hiroshi Sasano
KAKanon Aoki
Kanon Aoki
RARyutarou Arakawa
Ryutarou Arakawa
KHKazuhiko Hanada
Kazuhiko Hanada
Vancomycin is a synthetic antibiotic effective against Gram-positive pathogens. Although the clinical applicability of vancomycin for infants has been increasing, the pharmacokinetic data for vancomycin in extremely low-birth-weight infants are limited.

15 December 2022 in Journal of Microbiology & Biology Education
Verified
Journal Article
Open access
TATakuya Azechi
Takuya Azechi
HSHiroshi Sasano
Hiroshi Sasano
KSKuniyoshi Sato
Kuniyoshi Sato
RARyutarou Arakawa
Ryutarou Arakawa
KSKenichi Suzuki
Kenichi Suzuki
Antimicrobial resistance (AMR) is a global threat to human health. Education on antibiotics is essential for AMR prevention, and training should be provided for undergraduate pharmacy students.

29 October 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
HSHiroshi Sasano
Hiroshi Sasano
KHKazuhiko Hanada
Kazuhiko Hanada
Purpose: Enterococcal bacteremia is associated with high mortality and long-term hospitalization. Here, we aimed to investigate the clinical outcomes and evaluate the risk factors for mortality in adult patients treated with vancomycin (VCM) for vancomycin-susceptible Enterococcus faecium (E. faecium) bacteremia. Methods: This is a retrospective, record-based study. The data were collected from inpatients at a single university hospital between January 2009 and December 2020. The area under the curve (AUC) of VCM was calculated using the Bayesian approach. The primary outcome was a 30-day in-hospital mortality. Results: A univariate analysis showed significant differences in the concomitant use of vasopressors, history of the use of no clinically relevant activity antimicrobial agents against E. faecium, VCM plasma trough concentration, and renal dysfunction during VCM administration between the 30-day in-hospital mortality and survival groups. However, the groups’ AUC/minimum inhibitory concentration (MIC) were not significantly different. A multivariate analysis suggested that concomitant vasopressors may be an independent risk factor for 30-day in-hospital mortality (odds ratio, 7.81; 95% confidence interval, 1.16–52.9; p = 0.035). The VCM plasma trough concentrations and the AUC/MIC in the mortality group were higher than those in the surviving group. No association between the AUC/MIC and the treatment effect in E. faecium bacteremia was assumed, because the known, target AUC/MIC were sufficiently achieved in the mortality group. Conclusions: There may be no association between the AUC/MIC and the treatment effect in E. faecium bacteremia. When an immunocompromised host develops E. faecium bacteremia with septic shock, especially when a vasopressor is used in a patient with unstable hemodynamics, it may be difficult to treat it, despite efforts to ensure the appropriate AUC/MIC and therapeutic vancomycin concentration levels.

1 August 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
SKSanae Kubota
Sanae Kubota
HSHiroshi Sasano
Hiroshi Sasano
MSMai Suzuki
Mai Suzuki
YFYukiko Fukui
Yukiko Fukui
MCMasayoshi Chonan
Masayoshi Chonan
TNToshio Naito
Toshio Naito
Purpose: Whether the coronavirus disease 2019 (COVID-19) pandemic had any effect on the time between blood culture collection and administration of antibiotics in the outpatient Department of Emergency Medicine in a single university hospital in Japan was investigated, and the intervention carried out by the antimicrobial stewardship team (AST) to promote the appropriate use of antibiotics was examined. Patients and Methods: The monthly percentage of patients who visited the outpatient Department of Emergency Medicine between January 2019 and December 2021 and received an intravenous antibiotic within 3 hours of blood culture collection was calculated. The AST calculated a quality indicator (QI) based on the results of the investigation and started QI monitoring and hospital feedback. Results: From January 2020 to March 2021 (the third COVID-19 wave), the implementation rate of antibiotic administration within 3 hours after blood culture collection decreased as the COVID-19 pandemic spread, and the implementation rate tended to increase as the number of COVID-19-positive patients decreased. However, when the AST started monitoring and feedback from April 2021, although there was a temporary decline in the early stages of the fifth wave when the scale of infection was large, the implementation rate rose and was maintained by AST intervention. (the fourth and the fifth COVID-19 waves) (P< 0.01). Also, the implementation rate was significantly lower during the COVID-19 pandemic than during the non- pandemic (P< 0.05). Conclusion: The early COVID-19 pandemic may have affected the delay in time from blood culture collection to antibiotic administration. Later, in recurring COVID-19 pandemics, AST intervention eliminated this problem. When a bacterial infection such as sepsis is suspected, delayed treatment can be prevented by promptly collecting a blood culture, irrespective of concerns about COVID-19 infection. Calculating the QI may promote AST activities and the appropriate use of antibiotics.

12 March 2022 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
HSHiroshi Sasano
Hiroshi Sasano
TYToshihiro Yoshizawa
Toshihiro Yoshizawa
MSMai Suzuki
Mai Suzuki
YFYukiko Fukui
Yukiko Fukui
RARyutarou Arakawa
Ryutarou Arakawa
TNToshio Naito
Toshio Naito
A 56-year-old woman with a history of connective tissue disease developed fever, and Bacillus cereus (B. cereus) was detected in blood cultures. Therefore, treatment with vancomycin (VCM) was initiated. Since her blood cultures persistently detected B. cereus despite peripheral intravenous catheter replacement and VCM treatment, concomitant treatment with gentamicin (GM) was started. Blood cultures then became negative. Persistent B. cereus bacteremia responded to combination therapy with VCM and GM. This combination therapy may increase the risk of developing renal dysfunction, but the risk can be mitigated by appropriate therapeutic drug monitoring (TDM) and dose adjustments to achieve successful treatment.

7 April 2023 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
NKNoriko Koishi
Noriko Koishi
HSHiroshi Sasano
Hiroshi Sasano
TYToshihiro Yoshizawa
Toshihiro Yoshizawa
MSMika Shikuri
Mika Shikuri
HMHiroshi Matsumoto
Hiroshi Matsumoto
TNToshio Naito
Toshio Naito
An 80-year-old woman underwent pancreatoduodenectomy. Post-operation, she experienced a fever, and a culture of blood revealed metallo-beta-lactamase-producing Raoultella ornithinolytica. For treatments with aminoglycoside antimicrobial agents, a therapeutic drug monitoring-based dosing design can lower the risk of adverse events and enable appropriate treatment. Key Clinical Message. When aminoglycoside antimicrobial agents are administered for MBL-producing bacteremia, prescription suggestions based on TDM by antimicrobial stewardship team can reduce the occurrence of adverse events and enable appropriate treatment.